Impact of Adjunctive VNS on Drug Load, Depression Severity, and Number of Neuromodulatory Maintenance Treatments

Erhan Kavakbasi,Helen Bauermeister,Lars Lemcke,Bernhard T. Baune
DOI: https://doi.org/10.3390/brainsci14020159
IF: 3.333
2024-02-05
Brain Sciences
Abstract:Vagus nerve stimulation (VNS) is a long-term adjunctive treatment option in patients with difficult-to-treat depression (DTD). A total of n = 20 patients (mean age 52.6 years) were included in the multicenter, prospective, observational, naturalistic RESTORE-LIFE study and were treated with adjunctive VNS as an add-on to treatment as usual. Exploratory and secondary outcome parameters from a single center were investigated for this present analysis. The overall mean drug load slightly decreased from 4.5 at baseline to 4.4 at 12 months (Z = −0.534, p = 0.594). The drug load was lower in previous electroconvulsive therapy (ECT) responders than in non-responders. There was a reduction in the mean number of hospitalizations per month after VNS implantation (Z = 1.975, p = 0.048) and a significant decrease in the mean Montgomery Åsberg Depression Rating Scale (MADRS) score from 27.3 at baseline to 15.3 at 12 months (T = 4.230, degree of freedom (df) = 19, p = 0.001). A history of ECT response at baseline was associated with greater improvement in the MADRS score after 12 months of VNS (F = 8.171, p = 0.013). The number of neuromodulatory maintenance treatments decreased during the follow-up period. In summary, there was an alleviation in the burden of illness among DTD patients treated with VNS.
neurosciences
What problem does this paper attempt to address?
The paper aims to explore the impact of Vagus Nerve Stimulation (VNS) as an adjunctive treatment on medication load, depression severity, and the frequency of neurostimulation maintenance treatments in patients with Treatment-Resistant Depression (TRD). Specifically, the study focuses on the following points: 1. **Changes in medication load**: Researchers evaluated whether there was a change in patients' medication load from baseline to the 12-month follow-up period. 2. **Changes in depression severity**: By analyzing changes in Montgomery-Åsberg Depression Rating Scale (MADRS) scores, researchers assessed whether there was a significant improvement in patients' depressive symptoms. 3. **Changes in hospitalization frequency**: Researchers compared the monthly hospitalization frequency of patients before and after VNS implantation. 4. **Changes in the frequency of neurostimulation maintenance treatments**: Researchers examined the changes in the frequency of Electroconvulsive Therapy (ECT) or esketamine maintenance treatments during the VNS treatment period. Additionally, the study paid special attention to the differences in the above indicators between patients who previously responded to ECT and those who did not. Overall, the study aims to evaluate the effectiveness of VNS as an adjunctive treatment in reducing the disease burden for TRD patients.